SILUMBRA suvorexant 20mg tablet blister pack

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

suvorexant, Quantity: 20 mg

Disponible desde:

Merck Sharp & Dohme (Australia) Pty Ltd

Designación común internacional (DCI):

suvorexant

formulario farmacéutico:

Tablet, film coated

Composición:

Excipient Ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; copovidone; croscarmellose sodium; titanium dioxide; hypromellose; triacetin

Vía de administración:

Oral

Unidades en paquete:

30 tablets, 3 tablets, 10 tablets

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

SILUMBRA is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Following initiation of treatment, continuation should be re-evaluated after 3 months [see Pharmacodynamic Properties, Clinical trials and Adverse Effects (Undesirable Effects) for clinical trial durations].

Resumen del producto:

Visual Identification: White, round, biconvex, film coated tablet, marked with MSD logo and 335 on one side, and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Estado de Autorización:

Registered

Fecha de autorización:

2016-11-16